RivaCap 1.5mg Capsule 10pcs

RivaCap Capsule is indicated for the symptomatic treatment of:

• Mild to moderately severe Alzheimer’s dementia
• Mild to moderately severe dementia associated with Idiopathic Parkinson’s disease

Rivastigmine Capsule

The capsules should be taken twice daily with morning and evening meals.

Initial Dose

• 1.5 mg twice daily

Dose Titration

• If well tolerated after at least 2 weeks, increase to 3 mg twice daily
• Further increases to 4.5 mg and then 6 mg twice daily may be considered after a minimum of 2 weeks at each dose level

Maintenance Dose

• Effective dose range: 3 mg to 6 mg twice daily
• Maximum recommended dose: 6 mg twice daily

Treatment may continue as long as clinical benefit is maintained.

Re-initiation of Therapy

If treatment is interrupted for more than several days, restart at 1.5 mg twice daily and retitrate gradually.

Rivastigmine Transdermal Patch

Initial Dose

• 4.6 mg/24 hours patch once daily

Dose Escalation

• After at least 4 weeks, increase to 9.5 mg/24 hours if tolerated
• After another minimum 4 weeks, may increase to 13.3 mg/24 hours

Recommended Maintenance Doses

• Mild to moderate Alzheimer’s disease and Parkinson’s disease dementia: 9.5 mg/24 hr or 13.3 mg/24 hr
• Severe Alzheimer’s disease: 13.3 mg/24 hr

Apply one patch daily on intact skin and replace every 24 hours.

রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন।

Administration

• Apply only one patch at a time
• Replace the old patch with a new one every 24 hours
• Your doctor may adjust the dose according to individual response and tolerability

Drug Interactions

• May enhance the effects of succinylcholine-type muscle relaxants during anesthesia
• Concomitant use with other cholinomimetic agents is not recommended
• May interfere with anticholinergic medications
• No significant pharmacokinetic interactions have been observed with digoxin, warfarin, diazepam, or fluoxetine

Contraindications

RivaCap is contraindicated in patients with:

• Hypersensitivity to rivastigmine
• Allergy to carbamate derivatives

Side Effects

Common Adverse Effects

• Nausea
• Vomiting
• Diarrhea
• Weight loss
• Loss of appetite

Female patients may be more susceptible to gastrointestinal side effects and weight reduction.

Pregnancy & Lactation

Pregnancy

There are insufficient clinical data regarding use during pregnancy. Rivastigmine should only be used if clearly necessary.

Lactation

Animal studies show excretion into milk. Since it is unknown whether rivastigmine passes into human breast milk, breastfeeding is not recommended during therapy.

Precautions & Warnings

Use cautiously in patients with:

• Sick sinus syndrome or cardiac conduction disorders
• Asthma or chronic obstructive pulmonary disease
• Renal impairment
• Mild to moderate hepatic impairment
• History of seizures
• Urinary obstruction
• Gastric ulcer risk due to increased gastric acid secretion

Rivastigmine may worsen extrapyramidal symptoms in Parkinson’s disease patients. Regular monitoring of body weight is recommended.

Use in Special Populations

Renal & Hepatic Impairment

Patients with moderate renal impairment or mild-to-moderate hepatic impairment may require careful dose titration based on tolerability.

Pediatric Use

RivaCap is not recommended for use in children.

Overdose Effects

Symptoms of overdose may include:

• Nausea
• Vomiting
• Diarrhea
• Hallucinations
• Hypertension
• Bradycardia or fainting

Most overdose cases resolve with supportive care. In severe cases, atropine sulfate may be used as an antidote under medical supervision.

Therapeutic Class

Drugs for Dementia

Storage Conditions

Store in a cool and dry place, protected from light and moisture. Keep out of the reach of children.